US biotech MacroGenics (Nasdaq: MGNX) has inked deals with Provention Bio involving two clinical-stage assets. Provention has acquired all rights to teplizumab, to be further developed as PRV-031, and licensing rights to MGD010 for development as PRV-3279.
"Our agreements with MacroGenics expand Provention's pipeline with two additional clinical-stage assets that align perfectly with our mission to intercept or prevent immune-mediated diseases," explained Ashleigh Palmer, co-founder and chief executive of Provention Bio, adding: "In less than a year since announcing our founding financing, Provention has secured five clinical stage assets in the burgeoning field of disease prevention and interception."
"Given MacroGenics' current focus on its immuno-oncology pipeline, we believe Provention Bio will be an excellent partner to progress these programs and potentially bring these innovative medicines to patients suffering from serious autoimmune disorders," explained Scott Koenig, president and chief executive of MacroGenics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze